Published in Thromb Haemost on December 27, 1982
Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) (1985) 1.42
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol (2007) 4.55
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br (2007) 2.53
Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation (2000) 2.41
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost (2003) 1.95
Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 1.94
A rapid and reliable DNA preparation method for screening a large number of yeast clones by polymerase chain reaction. Nucleic Acids Res (1995) 1.84
Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation (1997) 1.69
Antithrombotic therapy for venous thromboembolic disease. Chest (1998) 1.67
Improving information to Italian cancer patients: results of a randomized study. Ann Oncol (2004) 1.60
Impedance plethysmography in the diagnosis of asymptomatic deep vein thrombosis in hip surgery. A venography-controlled study. Arch Intern Med (1991) 1.60
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost (2003) 1.57
Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes. Heart (2007) 1.47
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol (1992) 1.43
Hybridization of single-stranded DNA targets to immobilized complementary DNA probes: comparison of hairpin versus linear capture probes. Nucleic Acids Res (2001) 1.42
Pain management in internal medicine and effects of a standardised educational intervention: the FADOI-DOMINO study. Int J Clin Pract (2014) 1.40
Additive effect of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemost (1989) 1.39
Spiral computed tomography is the first-line chest imaging test for acute pulmonary embolism: no. J Thromb Haemost (2005) 1.38
Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research. Am J Clin Oncol (1989) 1.38
Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol (1999) 1.19
Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res (2010) 1.18
Isolated monoparesis following stroke. J Neurol Neurosurg Psychiatry (2005) 1.17
Intravenous thrombolysis in acute myocardial infarction. Chest (2001) 1.13
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost (2010) 1.12
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol (1991) 1.10
Natural history of fetal rat cardiomyocytes transplanted into adult rat myocardial scar tissue. Circulation (1997) 1.10
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation (1997) 1.10
Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology (1992) 1.09
Assessment of nausea. Eur J Clin Pharmacol (1990) 1.08
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci (1991) 1.08
Cervical artery dissection: emerging risk factors. Open Neurol J (2010) 1.08
Cryptogenic stroke: time to determine aetiology. J Thromb Haemost (2008) 1.06
Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol (1991) 1.06
Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost (2011) 1.05
Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med (2000) 1.03
Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost (2013) 1.02
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest (1998) 0.99
Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain. Pediatr Res (1996) 0.99
Antiemetics in cancer chemotherapy: historical perspective and current state of the art. Support Care Cancer (1994) 0.96
Elevated insulin-like growth factor-I and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy. A possible mechanism. Circulation (1998) 0.96
Bolus thrombolysis in venous thromboembolism. Chest (1992) 0.96
Arterial hypertension as risk factor for spontaneous cervical artery dissection. A case-control study. J Neurol Neurosurg Psychiatry (2006) 0.96
Epidemiological survey on multiple sclerosis in Italy. Riv Patol Nerv Ment (1976) 0.95
Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb Haemost (1990) 0.95
Platelets and asthma. Lancet (1985) 0.95
Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J (2002) 0.95
Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med (1989) 0.95
Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from simulated ischemia. J Thorac Cardiovasc Surg (1998) 0.95
Simultaneous isolation of total cellular RNA and DNA from tissue culture cells using phenol and lithium chloride. Genet Anal Tech Appl (1990) 0.94
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost (2007) 0.94
Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood (1993) 0.94
A pilot study of metoclopramide, dexamethasone, diphenhydramine and acupuncture in women treated with cisplatin. Cancer Chemother Pharmacol (1990) 0.93
Oral anticoagulation in atrial fibrillation: A pan-European patient survey. Eur J Intern Med (2007) 0.93
Platelet activation and allergic asthma. N Engl J Med (1982) 0.93
Platelets release their lysosomal content in vivo in humans upon activation. Thromb Haemost (2000) 0.93
Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost (2010) 0.93
Platelet activation in psoriasis. Thromb Haemost (1985) 0.92
Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood (1985) 0.92
A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol (1990) 0.92
Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations. Ann Neurol (1993) 0.92
Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost (2011) 0.89
Acute thrombocytopenia following oral cholecystography with iopanoic acid. Clin Toxicol (1981) 0.89
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. Bone Joint J (2013) 0.89
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost (2010) 0.89
Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis. Blood Coagul Fibrinolysis (1992) 0.89
The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and identification of a pseudogene. Gene (1997) 0.88
Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost (2005) 0.88
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis (2000) 0.88
Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost (2005) 0.88
Prior use of antithrombotic agents and neurological functional outcome at discharge in patients with ischemic stroke. J Thromb Haemost (2006) 0.87
Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. J Allergy Clin Immunol (1993) 0.87
Quality of life: gynaecological cancers. Ann Oncol (2001) 0.87
Inferior vena caval defects and the venous circulation. Chest (1987) 0.87
A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation (1985) 0.85
Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost (2010) 0.85
Incidental venous thromboembolism in oncology patients. J Thromb Haemost (2012) 0.85
Diagnosis of deep-vein thrombosis using an objective Doppler method. Ann Intern Med (1990) 0.84
Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost (2007) 0.84
Laryngeal cancer: long-term follow-up of respiratory functions after laryngectomy. Respiration (1984) 0.83
Comparative studies of various antiemetic regimens. Support Care Cancer (1996) 0.83
Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost (2011) 0.83
Protein kinase C inhibitors enhance G-protein induced phospholipase A2 activation in intact human platelets. FEBS Lett (1996) 0.83
Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography--an overview analysis. Thromb Haemost (1996) 0.83
Acute pulmonary embolism: risk stratification in the emergency department. Intern Emerg Med (2007) 0.83
Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep (1985) 0.83
Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. Blood Coagul Fibrinolysis (1993) 0.83
"In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Eur J Clin Pharmacol (1990) 0.82
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol (2003) 0.82